{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05442190",
            "orgStudyIdInfo": {
                "id": "HPN-PSR-01"
            },
            "organization": {
                "fullName": "Soligenix",
                "class": "INDUSTRY"
            },
            "briefTitle": "Topical SGX302 for Mild-to-Moderate Psoriasis",
            "officialTitle": "Phase 2 Study Evaluating SGX302 (Synthetic Hypericin) in the Treatment of Mild-to-Moderate Psoriasis",
            "therapeuticArea": [
                "Dermatology"
            ],
            "study": "topical-for-mild-to-moderate-psoriasis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-12-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-06-28",
            "studyFirstSubmitQcDate": "2022-06-28",
            "studyFirstPostDateStruct": {
                "date": "2022-07-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Soligenix",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "To evaluate SGX302 (topical hypericin ointment) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis."
        },
        "conditionsModule": {
            "conditions": [
                "Psoriasis",
                "Plaque Psoriasis",
                "Psoriasis Vulgaris"
            ],
            "keywords": [
                "Hypericin"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "This is a 2 part study. All protocol procedures, timing for schedule of events and assessments are identical for Parts A and B. In Part A, 5-10 patients will be assigned open-label SGX302. Once the tolerability and response to SGX302 has been established, Part B of the protocol will commence. In Part B, approximately 32 patients will be randomized to double-blind treatment groups at a ratio 1:1 of active drug to a placebo ointment.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 42,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "SGX302 (Ointment with 0.25 % Hypericin)",
                    "type": "EXPERIMENTAL",
                    "description": "SGX302 (0.25 % hypericin) ointment will be applied to lesions and treated with visible light 24\u00b16 hours later starting at 5 J/cm\\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.",
                    "interventionNames": [
                        "Drug: Hypericin"
                    ]
                },
                {
                    "label": "Placebo (Ointment without Hypericin)",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo ointment will be applied to lesions and treated with visible light 24\u00b16 hours later starting at 5 J/cm\\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Hypericin",
                    "description": "SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment.",
                    "armGroupLabels": [
                        "SGX302 (Ointment with 0.25 % Hypericin)"
                    ],
                    "otherNames": [
                        "SGX302"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo ointment is identical to SGX302 ointment (color matched) but it does not contain hypericin.",
                    "armGroupLabels": [
                        "Placebo (Ointment without Hypericin)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of patients that achieve a 0 or 1 score using the 5-point Investigator's Global Assessment scale",
                    "description": "The percentage of patients in each treatment group that achieve a 0 or 1 score (Clear or Almost Clear) evaluation using the 5-point Investigator's Global Assessment (IGA) scale.\n\nThe 5-point IGA scale:\n\n* Score 0: Clear - No signs of psoriasis; post-inflammatory hyperpigmentation may be present\n* Score 1: Almost Clear - No thickening; normal to pink coloration; no to minimal focal scaling\n* Score 2: Mild - Just detectable to mild thickening; pink to light red coloration; predominantly fine scaling\n* Score 3: Moderate - Clear distinguishable to moderate thickening; dull to bright red; moderate scaling\n* Score 4: Severe - Severe thickening with hard edges; bright to deep red coloration; severe/coarse scaling covering almost all lesions",
                    "timeFrame": "18 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of patients achieving a \u226575% improvement in Psoriasis Area and Severity Index",
                    "description": "The percentage of patients in each treatment group that achieve a \u226575% improvement in Psoriasis Area and Severity Index (PASI 75).\n\nPASI is a combined assessment of lesion severity and affected area into a single score. The body is divided into 4 areas for scoring: head, arms, trunk and legs. Each area is scored by itself and scores are combined for a final PASI. For each area, scores of erythema, thickness and scale are scored on a scale of 0 (clear) to 4 (maximum). For each area, percent of skin involved is estimated: 0 = 0%, 1= 0 to \u226410%, 2 = 10 to \\<30%, 3 = 30 to \\<50%, 4 = 50 to \\<70%, 5 = 70 to \u226490%, 6 = 90 to100%. Final PASI = (sum of severity parameters for each area)\\*(area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)).",
                    "timeFrame": "18 weeks"
                },
                {
                    "measure": "Number of patients achieving a \u226590% improvement in Psoriasis Area and Severity Index",
                    "description": "The percentage of patients in each treatment group that achieve a \u226590% improvement in Psoriasis Area and Severity Index (PASI 90).\n\nThe calculation of PASI was previously described.",
                    "timeFrame": "18 weeks"
                },
                {
                    "measure": "Number of patients achieving a 100% improvement in Psoriasis Area and Severity Index",
                    "description": "The percentage of patients in each treatment group that achieve a 100% improvement in Psoriasis Area and Severity Index (PASI 100).\n\nThe calculation of PASI was previously described.",
                    "timeFrame": "18 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6-months duration that involves the body (trunk and/or limbs) that is amenable to topical treatment and opaque coverage after application.\n* Have a static Investigator Global Assessment (IGA)/Psoriasis Area and Severity Index (PASI) of disease severity of mild or moderate on the body (trunk and/or limbs).\n* Have lesions involving 2-30% of the body (trunk and/or limbs). For subjects with scalp psoriasis included in the treatment area, the total treatment area on body and scalp must not exceed 30%.\n\nExclusion Criteria:\n\n* Use of topical anti psoriatic therapy within one week prior to the beginning of the study and willing to not use other psoriasis treatments for 4 weeks following completion of the treatment portion of the study.\n* Received systemic biologic therapy to treat psoriasis within 12 weeks prior to the beginning of the study.\n* Received systemic psoriasis therapy within 4 weeks prior to the beginning of the study.\n* Received phototherapy (including laser) or photodynamic (light activated drug) therapy within 4 weeks prior to the beginning of the study.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Christopher Pullion, DO",
                    "role": "CONTACT",
                    "phone": "609-538-8200",
                    "email": "cpullion@soligenix.com"
                }
            ],
            "locations": [
                {
                    "facility": "Therapeutics Clinical Research",
                    "status": "RECRUITING",
                    "city": "San Diego",
                    "state": "California",
                    "zip": "92123",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Noe Guerrero",
                            "role": "CONTACT",
                            "phone": "858-571-6800",
                            "phoneExt": "141"
                        },
                        {
                            "name": "Neal Bhatia, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.71533,
                        "lon": -117.15726
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011565",
                    "term": "Psoriasis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000017444",
                    "term": "Skin Diseases, Papulosquamous"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14422",
                    "name": "Psoriasis",
                    "asFound": "Psoriasis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M19713",
                    "name": "Skin Diseases, Papulosquamous",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000004965",
                    "term": "Hypericin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000928",
                    "term": "Antidepressive Agents"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M353466",
                    "name": "Hypericin",
                    "asFound": "Moxetumomab pasudotox",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4247",
                    "name": "Antidepressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}